Similar to other FDA-approved PD-1/PD-L1-targeted therapies, atezolizumab is also associated with adverse immune responses, including grade 1–4 immune-mediated colitis, hepatitis, and pneumonitis [84]. This evidence concerns the gene PDCD1 and pneumonitis.